RGNA: Investor Sentiment and Bull/Bear Views
Buzzberg insights
Attention & activity
- unique authors
- 0
- vs usual
- -100%
24h0
30d avg / day0
- unique authors
- 1
- vs usual
- New
7d1
4wk avg / week0
Author calls
What authors recommend
- Long
- —Authors: 0
- Short
- —Authors: 0
- Avoid
- —Authors: 0
- Long
- 0.0%Authors: 0
- Short
- 0.0%Authors: 0
- Avoid
- 100.0%Authors: 1
Author positions
What authors disclose
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
- Long
- —Authors: 0
- Short
- —Authors: 0
- Trimmed
- —Authors: 0
- Closed
- —Authors: 0
Feed & authors
- ideas
- 1
- Authors
- 1
- Sources
- 1
Call performance
Performance since each author’s call.
| Author | Direction | Return |
|---|---|---|
| No data yet | ||
Best calls over the past year · return since each call
Sentiment
Attention
0-100%vs usual
unique authors
30d avg / day 0
Attention
1Newvs usual
unique authors
4wk avg / week 0
Loading chart...
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
13:15
Nov 19
Nov 19
r/biotechplays
Reddit
RegenLab IPO riskier than headline revenue suggests
Ahead of its Nasdaq IPO, RegenLab shows ~$49M 2025 revenue but also ~$21M debt, a $12.8M working capital deficit, a $2.44M unsecured loan to the CEO and a 2025 net loss with going-concern concerns. The author also cites significant European patent setbacks for a business built on proprietary medical technology, making the IPO riskier than headline numbers suggest. Main risk to the bearish view is that the real revenue and MiMedx distribution agreement provide enough upside to justify the risks.